SETD1A Drives Stemness by Reprogramming the Epigenetic Landscape in Hepatocellular Carcinoma Stem Cells

Overview

Journal JCI Insight

Specialties Biomedical Engineering
General Medicine

Date 2023 Aug 15

PMID 37581938

Authors

Jianxu Chen

Zhijie Xu

Hongbin Huang

Yao Tang

Hong Shan

Fei Xiao

Affiliations

Soon will be listed here.

Abstract

Cancer stem cells (CSCs) are responsible for tumor progression and recurrence. However, the mechanisms regulating hepatocellular carcinoma (HCC) stemness remain unclear. Applying a genome-scale CRISPR knockout screen, we identified that the H3K4 methyltransferase SETD1A and other members of Trithorax group proteins drive cancer stemness in HCC. SET domain containing 1A (SETD1A) was positively correlated with poor clinical outcome in patients with HCC. Combination of SETD1A and serum alpha fetoprotein substantially improved the accuracy of predicting HCC relapse. Mechanistically, SETD1A mediates transcriptional activation of various histone-modifying enzymes, facilitates deposition of trimethylated H3K4 (H3K4me3) and H3K27me3, and activates oncogenic enhancers and super-enhancers, leading to activation of oncogenes and inactivation of tumor suppressor genes simultaneously in liver CSCs. In addition, SETD1A cooperates with polyadenylate-binding protein cytoplasmic 1 to regulate H3K4me3 modification on oncogenes. Our data pinpoint SETD1A as a key epigenetic regulator driving HCC stemness and progression, highlighting the potential of SETD1A as a candidate target for HCC intervention and therapy.

Citing Articles

Potential mechanism of circKIAA1429 accelerating the progression of hepatocellular carcinoma.

Yuan Y, Huang J, Wei G, Hu G, Yu H, Tao Y Infect Agent Cancer. 2025; 20(1):12.

PMID: 40025575 PMC: 11872318. DOI: 10.1186/s13027-025-00645-3.

ATP6V1D drives hepatocellular carcinoma stemness and progression via both lysosome acidification-dependent and -independent mechanisms.

Xu Z, Liu R, Ke H, Xu F, Yang P, Zhang W Autophagy. 2024; 21(3):513-529.

PMID: 39316516 PMC: 11849949. DOI: 10.1080/15548627.2024.2406186.

SLC4A11 mediates ammonia import and promotes cancer stemness in hepatocellular carcinoma.

Elaimy A, El-Derany M, James J, Wang Z, Pearson A, Holcomb E JCI Insight. 2024; 9(21).

PMID: 39287988 PMC: 11601557. DOI: 10.1172/jci.insight.184826.

The intricate interplay between cancer stem cells and cell-of-origin of cancer: implications for therapeutic strategies.

Bamodu O, Chung C, Pisanic 2nd T, Wu A Front Oncol. 2024; 14:1404628.

PMID: 38800385 PMC: 11116576. DOI: 10.3389/fonc.2024.1404628.

TMX2 potentiates cell viability of hepatocellular carcinoma by promoting autophagy and mitophagy.

Zhang W, Tang Y, Yang P, Chen Y, Xu Z, Qi C Autophagy. 2024; 20(10):2146-2163.

PMID: 38797513 PMC: 11423672. DOI: 10.1080/15548627.2024.2358732.

References

Creyghton M, Cheng A, Welstead G, Kooistra T, Carey B, Steine E . Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A. 2010; 107(50):21931-6. PMC: 3003124. DOI: 10.1073/pnas.1016071107. View

Si Y, Liu J, Shen H, Zhang C, Wu Y, Huang Y . Fisetin decreases TET1 activity and CCNY/CDK16 promoter 5hmC levels to inhibit the proliferation and invasion of renal cancer stem cell. J Cell Mol Med. 2018; 23(2):1095-1105. PMC: 6349178. DOI: 10.1111/jcmm.14010. View

Ali S, Justilien V, Jamieson L, Murray N, Fields A . Protein Kinase Cι Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma. Cancer Cell. 2016; 29(3):367-378. PMC: 4795153. DOI: 10.1016/j.ccell.2016.02.012. View

Lee T, Guan X, Ma S . Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications. Nat Rev Gastroenterol Hepatol. 2021; 19(1):26-44. DOI: 10.1038/s41575-021-00508-3. View

Zhao W, Ma B, Tian Z, Han H, Tang J, Dong B . Inhibiting CBX4 efficiently protects hepatocellular carcinoma cells against sorafenib resistance. Br J Cancer. 2021; 124(7):1237-1248. PMC: 8007794. DOI: 10.1038/s41416-020-01240-6. View

Wei X, Huo Y, Pi J, Gao Y, Rao S, He M . METTL3 preferentially enhances non-mA translation of epigenetic factors and promotes tumourigenesis. Nat Cell Biol. 2022; 24(8):1278-1290. DOI: 10.1038/s41556-022-00968-y. View

Chen Z, Gao Y, Yao L, Liu Y, Huang L, Yan Z . LncFZD6 initiates Wnt/β-catenin and liver TIC self-renewal through BRG1-mediated FZD6 transcriptional activation. Oncogene. 2018; 37(23):3098-3112. PMC: 5992127. DOI: 10.1038/s41388-018-0203-6. View

Wang C, Vegna S, Jin H, Benedict B, Lieftink C, Ramirez C . Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature. 2019; 574(7777):268-272. PMC: 6858884. DOI: 10.1038/s41586-019-1607-3. View

Zhu P, Wang Y, Huang G, Ye B, Liu B, Wu J . lnc-β-Catm elicits EZH2-dependent β-catenin stabilization and sustains liver CSC self-renewal. Nat Struct Mol Biol. 2016; 23(7):631-9. DOI: 10.1038/nsmb.3235. View

10.

Wang C, Cao Y, Yang C, Bernards R, Qin W . Exploring liver cancer biology through functional genetic screens. Nat Rev Gastroenterol Hepatol. 2021; 18(10):690-704. DOI: 10.1038/s41575-021-00465-x. View

11.

Morgan M, Shilatifard A . Reevaluating the roles of histone-modifying enzymes and their associated chromatin modifications in transcriptional regulation. Nat Genet. 2020; 52(12):1271-1281. DOI: 10.1038/s41588-020-00736-4. View

12.

Tsang F, Law C, Tang T, Cheng C, Chin D, Tam W . Aberrant Super-Enhancer Landscape in Human Hepatocellular Carcinoma. Hepatology. 2019; 69(6):2502-2517. DOI: 10.1002/hep.30544. View

13.

Asakura N, Nakamura N, Muroi A, Nojima Y, Yamashita T, Kaneko S . Expression of Cancer Stem Cell Markers EpCAM and CD90 Is Correlated with Anti- and Pro-Oncogenic EphA2 Signaling in Hepatocellular Carcinoma. Int J Mol Sci. 2021; 22(16). PMC: 8395527. DOI: 10.3390/ijms22168652. View

14.

Shepherd M, Li J, Wilson N, Oedekoven C, Li J, Belmonte M . Single-cell approaches identify the molecular network driving malignant hematopoietic stem cell self-renewal. Blood. 2018; 132(8):791-803. PMC: 6107881. DOI: 10.1182/blood-2017-12-821066. View

15.

Hogg S, Beavis P, Dawson M, Johnstone R . Targeting the epigenetic regulation of antitumour immunity. Nat Rev Drug Discov. 2020; 19(11):776-800. DOI: 10.1038/s41573-020-0077-5. View

16.

Hagiwara M, Yasumizu Y, Yamashita N, Rajabi H, Fushimi A, Long M . MUC1-C Activates the BAF (mSWI/SNF) Complex in Prostate Cancer Stem Cells. Cancer Res. 2020; 81(4):1111-1122. PMC: 8026569. DOI: 10.1158/0008-5472.CAN-20-2588. View

17.

Hoshii T, Cifani P, Feng Z, Huang C, Koche R, Chen C . A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response. Cell. 2018; 172(5):1007-1021.e17. PMC: 6052445. DOI: 10.1016/j.cell.2018.01.032. View

18.

Meng X, Xiao W, Sun J, Li W, Yuan H, Yu T . CircPTK2/PABPC1/SETDB1 axis promotes EMT-mediated tumor metastasis and gemcitabine resistance in bladder cancer. Cancer Lett. 2022; 554:216023. DOI: 10.1016/j.canlet.2022.216023. View

19.

Li S, Shen L, Chen K . Association between H3K4 methylation and cancer prognosis: A meta-analysis. Thorac Cancer. 2018; 9(7):794-799. PMC: 6026618. DOI: 10.1111/1759-7714.12647. View

20.

Chen M, Chen X, Li S, Pan X, Gong Y, Zheng J . An Epigenetic Mechanism Underlying Chromosome 17p Deletion-Driven Tumorigenesis. Cancer Discov. 2020; 11(1):194-207. PMC: 8591992. DOI: 10.1158/2159-8290.CD-20-0336. View